Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00365235|
Recruitment Status : Completed
First Posted : August 17, 2006
Last Update Posted : January 12, 2012
|Condition or disease|
|Hyperlipidemia, Familial Combined Coronary Disease|
CHD is the leading cause of death in Mexico. Dyslipidemia that is characterized by high total cholesterol, high triglycerides, and low "good" high-density lipoprotein (HDL) cholesterol is a risk factor for developing CHD. Research has shown that the Mexican population has an increased tendency towards dyslipidemia, but it is not known what genetic factors contribute to this predisposition. This study will examine the genetic basis of FCHL, which is an inherited form of dyslipidemia characterized by elevated levels of total cholesterol and triglycerides. FCHL is a major contributing factor in CHD; 20% of individuals with CHD under the age of 60 have FCHL. The purpose of this study is to identify and characterize the specific DNA sequence variations that predispose Mexican individuals to FCHL. Results of this study may aid in the development of appropriate prevention and screening techniques.
This study will enroll individuals in Mexico who have FCHL. Participants will attend one study visit for blood collection and DNA sampling. Family members of participants will be contacted and asked to provide a DNA sample also. A select group of participants will return for a second study visit for RNA sampling. Study researchers will analyze participants' DNA and RNA samples, as well as two FCHL genes identified in previous research studies.
|Study Type :||Observational|
|Actual Enrollment :||998 participants|
|Official Title:||Genetic Susceptibility to Common Lipid Disorders in Mexico|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||June 2011|
- Identifying the specific genes that predispose Mexican individuals to FCHL [ Time Frame: Measured through the use of genetic samples ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00365235
|Instituto Nacional De Ciencias Medicas y Nutricion|
|Mexico City, Mexico, 14000|
|Principal Investigator:||Paivi E. Pajukanta, MD, PhD||David Geffen School of Medicine at UCLA, Department of Human Genetics|